Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.37 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24478860 | 0.83 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 | |
| SCHEMBL25963114 | 0.83 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 | |
| SCHEMBL25970268 | 0.83 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 | |
| SCHEMBL24635181 | 0.81 | LGALS3 (0.42) | LGALS3LGALS7; LGALS7BLGALS9LGALS1CA12 | |
| SCHEMBL19749908 | 0.79 | ALDH1A1 (0.44) | LGALS3ALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL20662400 | 0.79 | ALDH1A1 (0.44) | LGALS3ALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL25970258 | 0.78 | LGALS3 (0.42) | LGALS3LGALS7; LGALS7BLGALS9LGALS1CA12 | |
| SCHEMBL24478861 | 0.77 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 | |
| SCHEMBL23805518 | 0.76 | ALDH1A1 (0.39) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 | |
| SCHEMBL24478872 | 0.76 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253600-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128733-A1 | BIOORTHOGONAL COMPOSITIONS | TIE1, BBOX1, ST14 | LGALS3 466/4885LGALS7; LGALS7B 303/4885LGALS9 980/4885 |
| US-11253600-B2 | Bioorthogonal compositions | TIE1, BBOX1, ST14 | LGALS3 466/4885LGALS7; LGALS7B 303/4885LGALS9 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.